Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI119110

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

M G Wing, T Moreau, J Greenwood, R M Smith, G Hale, J Isaacs, H Waldmann, P J Lachmann, and A Compston

Molecular Immunopathology Unit, Medical Research Council Centre, Cambridge, United Kingdom.

Find articles by Wing, M. in: JCI | PubMed | Google Scholar

Molecular Immunopathology Unit, Medical Research Council Centre, Cambridge, United Kingdom.

Find articles by Moreau, T. in: JCI | PubMed | Google Scholar

Molecular Immunopathology Unit, Medical Research Council Centre, Cambridge, United Kingdom.

Find articles by Greenwood, J. in: JCI | PubMed | Google Scholar

Molecular Immunopathology Unit, Medical Research Council Centre, Cambridge, United Kingdom.

Find articles by Smith, R. in: JCI | PubMed | Google Scholar

Molecular Immunopathology Unit, Medical Research Council Centre, Cambridge, United Kingdom.

Find articles by Hale, G. in: JCI | PubMed | Google Scholar

Molecular Immunopathology Unit, Medical Research Council Centre, Cambridge, United Kingdom.

Find articles by Isaacs, J. in: JCI | PubMed | Google Scholar

Molecular Immunopathology Unit, Medical Research Council Centre, Cambridge, United Kingdom.

Find articles by Waldmann, H. in: JCI | PubMed | Google Scholar

Molecular Immunopathology Unit, Medical Research Council Centre, Cambridge, United Kingdom.

Find articles by Lachmann, P. in: JCI | PubMed | Google Scholar

Molecular Immunopathology Unit, Medical Research Council Centre, Cambridge, United Kingdom.

Find articles by Compston, A. in: JCI | PubMed | Google Scholar

Published December 15, 1996 - More info

Published in Volume 98, Issue 12 on December 15, 1996
J Clin Invest. 1996;98(12):2819–2826. https://doi.org/10.1172/JCI119110.
© 1996 The American Society for Clinical Investigation
Published December 15, 1996 - Version history
View PDF
Abstract

The administration of the immunosuppressive humanized monoclonal antibody CAMPATH 1-H, which recognizes CD52 on lymphocytes and monocytes, is associated with a first-dose cytokine-release syndrome involving TNFalpha, IFNgamma, and IL-6 clinically. In vitro models have been used to establish the cellular source and mechanism responsible for cytokine release, demonstrating that cytokine release is isotype dependent, with the rat IgG2b and human IgG1 isotype inducing the highest levels of cytokine release, which was inhibited with antibody to CD16, the low affinity Fc-receptor for IgG (FcgammaR). Cross-linking antibody opsonized CD4 T lymphocytes failed to stimulate TNFalpha release, which together with the observation that TNFalpha release by purified natural killer (NK) cells stimulated by fixed autologous CAMPATH 1-H-opsonized targets was inhibited with anti-CD16, indicates that cytokine release results from ligation of CD16 on the NK cells, rather than Fc-receptor (FcR)-dependent cross-linking of CD52 on the targeted cell. Since the hierarchy of isotypes inducing cytokine release in these cultures matches that seen clinically, we conclude that ligation of CD16 on NK cells is also responsible for cytokine release after injection of CAMPATH 1-H in vivo.

Version history
  • Version 1 (December 15, 1996): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts